nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-6D1CF66C·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Meta-analysis

Genome-wide meta-analysis of quantitatively measured generalized anxiety symptoms in individuals of European ancestry.

Skelton et al.Skelton, Mitchell, Assary et al.·2026·Nature human behaviour·10.1038/s41562-026-02476-7 ↗

Primary claim

We identified 80 independent genome-wide significant variants within 74 loci, 39 of which were newly associated with anxiety.

Well-supported · Well-powered meta-analysis of 693,869 individuals with standardized QC; novelty defined strictly against catalogued internalizing-trait associations
In brief

The largest quantitative anxiety GWAS to date delivers 74 loci and cross-ancestry polygenic signal, but its loci largely index broader neuroticism-related liability.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Abstract

Anxiety is heritable and exists on a continuum, with symptoms ranging from adaptive threat response to clinical disorder. Here we performed a genome-wide association meta-analysis of generalized anxiety symptom severity in 693,869 individuals of European ancestry from 14 cohorts. We identified 80 independent genome-wide significant variants within 74 loci, 39 of which were newly associated with anxiety. SNP-based heritability was 5.9% (posterior s.d. = 0.15%). Polygenic scores were significantly associated with anxiety symptom severity and disorder in European, African and South Asian ancestry samples (R2 = 1.2-2.9%). Significant genetic correlations (rg) were estimated with mental and physical health traits, including case-control anxiety, neuroticism and depression (rg = 0.71-0.85), irritable bowel syndrome (rg = 0.57), coronary artery disease, endometriosis and migraine (rg = 0.20-0.27). Gene-based and pathway analyses implicated synaptic and axonal processes, with enriched expression in the brain. These findings highlight the discovery power gained from analysing a quantitative trait rather than a case-control phenotype in anxiety genetics.

Key Claims

Primary finding · Well-supported

We identified 80 independent genome-wide significant variants within 74 loci, 39 of which were newly associated with anxiety.

Well-powered meta-analysis of 693,869 individuals with standardized QC; novelty defined strictly against catalogued internalizing-trait associations

Abstract; Results, Genome-wide association meta-analysis
Quote verified
Secondary · Well-supported

SNP-based heritability was 5.9% (posterior s.d. = 0.15%).

SBayesRC estimate with tight posterior SD, consistent with a prior quantitative anxiety estimate and discussed against liability-scale values

Abstract; Results, SNP-based heritability and genetic correlations with external traits
Quote verified
Secondary · Supported

Polygenic scores were significantly associated with anxiety symptom severity and disorder in European, African and South Asian ancestry samples (R2 = 1.2-2.9%).

Target samples of 1,303-3,452 drawn partly from a discovery cohort with overlap handling unstated; variance explained is small

Abstract; Results, Polygenic risk scores
Quote verified
Secondary · Supported

Significant genetic correlations (rg) were estimated with mental and physical health traits, including case-control anxiety, neuroticism and depression (rg = 0.71-0.85), irritable bowel syndrome (rg = 0.57), coronary artery disease, endometriosis and migraine (rg = 0.20-0.27).

Bonferroni-corrected LD score regression across 105 traits; correlations are associative and need not reflect horizontal pleiotropy

Abstract; Results, SNP-based heritability and genetic correlations with external traits
Quote verified
Secondary · Tentative

These findings highlight the discovery power gained from analysing a quantitative trait rather than a case-control phenotype in anxiety genetics.

Locus-count comparison against a largely overlapping, differently composed case-control study is not a controlled contrast

Abstract, final sentence; Discussion, final paragraph
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Scale and consistency of the discovery analysis

Meta-analysis of 693,869 individuals across 14 cohorts in 8 countries yields 80 independent genome-wide significant variants within 74 loci. Median I² for the LD-independent lead SNPs is 0%, and cross-cohort genetic correlations range from 0.64 to 0.97, indicating consistent effect estimates despite differing instruments.

↳ Results, Genome-wide association meta-analysis; Supplementary Tables 4 and 7

#methodological rigour

Conditional analyses reported with their own caveats

mtCOJO conditioning on neuroticism, case-control anxiety and depression is reported in full, including that only two loci survive conditioning on neuroticism, alongside standard-error inflation of 7-9% and sign changes in 17-20% of variants as evidence of instability. The Discussion draws the implication that many loci may index broader neuroticism-related liability.

↳ Results, Conditional analyses; Discussion, paragraph 4

#contribution

Advance delineated against the closest prior study

The paper reports that all 58 loci from the prior case-control anxiety GWAS show the same direction of effect here, with 19 reaching genome-wide significance, and names the five non-overlapping cohorts and approximate added sample. This makes the increment over prior work auditable rather than asserted.

↳ Results, Genome-wide association meta-analysis; Methods, Meta-analysis

#positioning

Limitations carried into interpretation

The European-ancestry restriction, the GAD-7's incomplete DSM-5 symptom coverage, measurement noise from recent-symptom scales, and the underpowered subgroup comparisons are each connected to a specific consequence for what can be concluded. The paper states it cannot be certain all cohorts captured the same underlying genetic architecture.

↳ Discussion, paragraphs 3-5

Limitations

#contribution

Power comparison against case-control is uncontrolled

The claim that quantitative phenotyping delivers superior discovery rests on comparing 74 loci here with 58 loci from a larger case-control study, but nine of the 14 cohorts overlap that study and sample composition differs by the availability of symptom versus diagnostic data. The comparison is suggestive rather than an identified contrast.

↳ Abstract, final sentence; Discussion, final paragraph; Methods, Meta-analysis

#methodological rigour

Subgroup equivalence checks are underpowered

Cohorts used six different symptom measures and mixed community and clinical ascertainment, but the paper reports that most pairwise cohort and subgroup genetic-correlation comparisons had heritability z-scores below 4. Equivalence of genetic architecture across instruments is therefore not established, only not contradicted.

↳ Results, Genome-wide association meta-analysis; Methods, Meta-analysis

#methodological rigour

Polygenic score validation rests on small samples

Target samples number 1,303 to 3,452 individuals with 218 to 407 cases, drawn partly from UK Biobank, which also contributes to discovery; how overlap was excluded is not described. The liability-scale conversion assumes 20% population prevalence against observed case fractions nearer 13-17%.

↳ Methods, PRSs; Results, Polygenic risk scores

#application pathway

Discovery restricted to European ancestry

All 14 discovery cohorts are European-ancestry, and cross-ancestry polygenic scores explain only 1.2-1.4% of variance in African and South Asian samples versus 2.9% in European. Population-specific risk loci cannot be identified from this design.

↳ Abstract; Results, Polygenic risk scores; Discussion, paragraph 5

Does this match your read? Add your assessment ↓

Nabu Commentary

The core discovery result is secure: 693,869 participants, standardized cohort quality control, inverse-variance meta-analysis, and a median I² of 0% across the LD-independent lead SNPs, with cross-cohort genetic correlations of 0.64 to 0.97 supporting consistency despite six different symptom instruments. Assessment turned on how much weight the conditional analyses should carry: conditioning on neuroticism leaves only two genome-wide significant loci, and although the paper reports the standard-error inflation and sign changes that make those results unstable, the finding bounds how far the loci can be read as anxiety-specific. The abstract's closing claim about the discovery power of quantitative phenotyping rests on a 74-versus-58 locus comparison with a study sharing nine of the 14 cohorts, which the Discussion hedges but the abstract does not. Polygenic-score validation is genuine but thin — target samples of 1,303 to 3,452, drawn partly from a discovery cohort, with liability-scale conversion assuming 20% prevalence against observed case fractions nearer 13-17%. The result is a competently executed, substantial discovery paper whose headline framing runs slightly ahead of what its own conditional analyses can carry.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
4.0±0.2

Contribution
4.0

The meta-analysis of 693,869 individuals yields 80 independent variants across 74 loci with 39 new for anxiety, a clearly delineated extension of the prior case-control discovery base. The score sits mid-band because nine of the 14 cohorts overlap the comparator study and conditioning on neuroticism leaves only two genome-wide significant loci, so the phenotype-specific component of the advance is not established.

Abstract; Results, Genome-wide association meta-analysis; Results, Conditional analyses

Conditioning on neuroticism ... resulted in 9 remaining genome-wide significant SNPs across 2 loci

Methodological Rigour
4.0

The pipeline is comprehensive: standardized cohort-level QC, MAF and imputation filters, presence in at least half the cohorts, inverse-variance METAL meta-analysis, Cochran's Q and I², cross-cohort LDSC, an LDSC intercept check, subgroup sensitivity analyses, mtCOJO conditioning with explicit instability caveats, and independent cross-ancestry PRS testing. The score stops mid-to-upper band because the paper states most subgroup and cohort correlation comparisons were underpowered, fine-mapping assumes one causal variant per locus, and PRS target samples are small with discovery-target overlap handling unstated.

Methods, Meta-analysis; Methods, PRSs; Results, Genome-wide association meta-analysis

most pairwise comparisons were not sufficiently powered

Reporting
4.1

The exposition moves cleanly from discovery through heritability, genetic correlations, conditioning, polygenic scores and annotation, with effect estimates, intervals and corrected thresholds attached to quantitative statements. The abstract does not carry the post-conditioning locus count, though the Discussion states plainly that many loci may index broader neuroticism-related liability.

Abstract; Discussion, paragraphs 3-4

Many genome-wide significant loci may therefore index a broader neuroticism-related liability

Positioning
4.1

Prior case-control GWAS, the two-item MVP analysis, UK Biobank symptom-grouping work and genomic structural equation modelling results are all engaged and the findings positioned against them. Limitations — European-only discovery, GAD-7's incomplete DSM-5 coverage, instrument and ascertainment heterogeneity — are each carried into an interpretive consequence rather than listed.

Main, paragraphs 2-4; Discussion, paragraphs 4-5

This limits the generalizability of our findings across anxiety disorders

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

The gene-based locus label differs from the primary GWAS count, and the text does not explain how UK Biobank discovery and PRS target participants were kept independent.

Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: not stated

Reference IntegrityClean

95 references in manuscript 95 of 95 checkable references found in an index 6 references confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Mental health · Anxiety disorders
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim rests on an observational genome-wide association meta-analysis, and the 39 newly identified anxiety loci have not been independently replicated in an external cohort.

From the paper
“the combination of these with deeply phenotyped clinical cohorts will be crucial for translating genetic insights into diagnostic and therapeutic advances”

The paper names possible real-world uses of its findings, namely diagnostic and therapeutic advances and drug target prioritisation, but does not specify who would act on them.

Pathway

Psychiatric genetics researchers and pharmaceutical target-discovery teams would use the implicated loci, genes and synaptic pathways to prioritise biological mechanisms and candidate drug targets for anxiety.

Barrier

The loci have very small individual effects with only 5.9% SNP-based heritability, so extensive functional validation and much larger diverse-ancestry studies are needed before any clinical or therapeutic application.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes

    Rossi, Sportelli, Kikidis, et al. · 2026 · Clinical medicine

    Primary claim

    Applying this framework to Psychiatric Genomics Consortium wave 3 genotypes identified 766 genes associated with schizophrenia

    Tentative
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  2. Shared proteomic landscape between arteriosclerosis and cardiovascular endpoints: a Mendelian randomization and observational study integrating AlphaFold3 for structural prediction

    Huang, Meena, Achtari, et al. · 2026 · Clinical medicine

    Primary claim

    We prioritized 10 proteins potentially causally associated with both the arteriosclerotic/atherosclerotic markers and cardiovascular events.

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats
  3. GWAS of extended prescription analgesic use identifies genetic loci in chronic pain

    Harlow, Uzochukwu, Fernando, et al. · 2026 · Clinical medicine

    Primary claim

    Integrating these genetic associations with functional data identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling.

    Tentative
    Evidence Score
    3.4±0.2
    Reliability
    Caveats

How the rubric works →